Basking in the glow of a collaboration involving Eli Lilly’s diabetes/weight loss blockbuster tirzepatide, BioAge Labs has completed an oversubscribed $170 million Series D financing, the proceeds of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results